Posters

Below is a full list of scientific posters and the conferences where they have been presented.  Due to poster file sizes impeding page download times, the previews below are low resolution.  For a high-resolution PDF of any poster, please email with your request.  Be sure to indicate which poster(s) are of interest.

BPX-01 for the treatment of inflammatory lesions of acne vulgaris

July 2018

DEF Essential Resource Meeting (DERM) 2018

Subset Analysis of IGA in Female Demographic in BPX-01 Topical Minocycline Gel Phase 2b Trial for the Treatment of Inflammatory Acne Vulgaris

December 2017

American Society for Cell Biology (ASBC) and European Molecular Biology Organization (EMBO)

BPX-01 Topical Minocycline Gel Reduces P. acnes-Induced Inflammatory Lesions in Mice

October 2017

Re-entering Antibacterial Discovery and Development Summit 2017

Development of Minocycline (BPX-01) as a Topical Treatment for Acne Vulgaris and Rosacea

October 2017

Fall Clinical Dermatology Conference

Visualization of Cutaneous Distribution of Minocycline of a Topical Gel in Human Facial Skin with Two-Photon Excited Fluorescence Lifetime Imaging Microscopy (FLIM) and Phasor Analysis

October 2017

Fall Clinical Dermatology Conference

Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study

July 2017

DEF Essential Resource Meeting (DERM) 2017

Safety, Efficacy and Patient Satisfaction of BPX-01 2% Minocycline Topical Gel for Acne Vulgaris

June 2017

Alabama Dermatology Society Summer Symposium

Results from a Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris

June 2017

World Preclinical Congress

Effectiveness and Safety of a Topical Hydrophilic Minocycline Gel Compared to a Topical Lipophilic Minocycline Gel

March 2017

Society of Toxicology

BPX-01 TOXICOLOGICAL EVALUATION OF 1% TOPICAL MINOCYCLINE GEL

March 2017

American Academy of Dermatology

DEVELOPMENT AND ASSESSMENT OF BPX-01, A NOVEL TOPICAL MINOCYCLINE GEL FOR TREATMENT OF ACNE VULGARIS

January 2017

Orlando Dermatology Aesthetic & Clinical Conference

INVOLVEMENT OF SEBACEOUS GLAND IN ACNE PATHOGENESIS

December 2016

Re-entering Antibacterial Discovery and Development Summit

THERAPEUTIC EFFECTS OF A TOPICAL MINOCYCLINE IN AN INFLAMMATORY ACNE ANIMAL MODEL

December 2016

ASCB Annual Meeting

Effects of Minocycline Against Propionibacterium Acnes-induced Inflammation in Human Keratinocytes

November 2016

Annual Las Vegas Dermatology Seminar

BPX-01 Minocycline 1% Topical Gel for the Treatment of Acne Vulgaris

September 2016

Coastal Dermatology Symposium

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

July 2016

DEF Essential Resource Meeting

A Comparative Pharmacokinetic Study of Oral Minocycline to Topical Minocycline

March 2016

Society of Toxicology Annual Meeting

New BPX-01 Formulations Improve In Vitro and In Vivo Delivery of Minocycline in Minipigs

March 2016

American Academy of Dermatology

Nonclinical Toxicology of BPX-01, a Novel Topical Formulation for Treatment of Acne Vulgaris

January 2016

2016 Winter Clinical Dermatology Conference

BPX-01: A Novel and Safe Treatment for Acne Vulgaris

December 2015

ASCB Annual Meeting

BPX-01: A Novel Formulation for the Treatment of Acne

November 2015

SDEF Dermatology Seminar

BPX-01: In Vivo Delivery and Safety of Minocycline Topical Gel

BPX-04 for the treatment of inflammatory lesions of rosacea

May 2018

Congress of Clinical Dermatology

Early Data from BPX-04 Topical Minocycline Gel for Rosacea Supported by Data from BPX-01 Topical Minocycline Gel for Acne: A Review

January 2018

Maui Derm for Dermatologists 2018

Cutaneous Tolerability of a Novel Topical Minocycline Gel for the Treatment of Rosacea

January 2018

2018 Winter Clinical Dermatology Conference

Early Onset of Efficacy Using a 1% and 2% Topical Minocycline Gel for the Treatment of Rosacea: a Small Open Label Study